Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0019 | 0.0231 | 0.0769 |
Schistosoma mansoni | terminal deoxycytidyl transferase | 0.0019 | 0.0231 | 0.0231 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0019 | 0.0231 | 0.5034 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.0402 | 1 |
Loa Loa (eye worm) | ImpB/MucB/SamB family protein | 0.0019 | 0.0231 | 0.0015 |
Leishmania major | hypothetical protein, conserved | 0.0025 | 0.0402 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.0402 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0025 | 0.0402 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.0402 | 1 |
Echinococcus granulosus | tyrosine protein phosphatase non receptor type | 0.0354 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0019 | 0.0231 | 0.0769 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0019 | 0.0231 | 1 |
Schistosoma mansoni | rab geranylgeranyl transferase alpha subunit | 0.0019 | 0.0231 | 0.0231 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0019 | 0.0231 | 1 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0019 | 0.0231 | 1 |
Loa Loa (eye worm) | protein-tyrosine phosphatase | 0.0354 | 1 | 1 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0019 | 0.0231 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0019 | 0.0217 | 0.0217 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.0231 | 0.5034 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.0231 | 0.5034 |
Giardia lamblia | DINP protein human, muc B family | 0.0019 | 0.0231 | 1 |
Echinococcus granulosus | dna polymerase eta | 0.0019 | 0.0231 | 0.0231 |
Leishmania major | DNA polymerase kappa, putative | 0.0019 | 0.0231 | 0.0769 |
Echinococcus granulosus | dna polymerase kappa | 0.0019 | 0.0231 | 0.0231 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0019 | 0.0231 | 0.0769 |
Echinococcus multilocularis | terminal deoxycytidyl transferase rev1 | 0.0019 | 0.0231 | 0.0231 |
Echinococcus multilocularis | tyrosine protein phosphatase non receptor type | 0.0354 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.0402 | 0.0189 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.0231 | 0.5034 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0019 | 0.0217 | 0.5 |
Trypanosoma brucei | unspecified product | 0.0019 | 0.0231 | 0.5034 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.0231 | 0.5034 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0019 | 0.0217 | 0.5 |
Echinococcus multilocularis | dna polymerase eta | 0.0019 | 0.0231 | 0.0231 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.0402 | 1 |
Brugia malayi | hypothetical protein | 0.0025 | 0.0402 | 0.0262 |
Schistosoma mansoni | ap endonuclease | 0.0019 | 0.0217 | 0.0217 |
Schistosoma mansoni | DNA polymerase eta | 0.0019 | 0.0231 | 0.0231 |
Leishmania major | DNA polymerase eta, putative | 0.0019 | 0.0231 | 0.0769 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0019 | 0.0231 | 0.0769 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.0231 | 0.5034 |
Schistosoma mansoni | protein tyrosine phosphatase non-receptor type nt1 | 0.0354 | 1 | 1 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0019 | 0.0231 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0025 | 0.0402 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.0231 | 0.5034 |
Leishmania major | DNA polymerase kappa, putative,DNA polymerase IV, putative | 0.0019 | 0.0231 | 0.0769 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0019 | 0.0217 | 0.4621 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0019 | 0.0231 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.0231 | 0.5034 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0019 | 0.0231 | 0.5034 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0025 | 0.0402 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0019 | 0.0231 | 0.5034 |
Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0231 | 0.0015 |
Echinococcus granulosus | terminal deoxycytidyl transferase rev1 | 0.0019 | 0.0231 | 0.0231 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0019 | 0.0231 | 0.0769 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0019 | 0.0231 | 0.0089 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.0231 | 0.5034 |
Echinococcus multilocularis | dna polymerase kappa | 0.0019 | 0.0231 | 0.0231 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0019 | 0.0217 | 0.0217 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.0231 | 0.5034 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0019 | 0.0217 | 0.0074 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.0231 | 0.5034 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0019 | 0.0231 | 1 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0019 | 0.0231 | 0.0089 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0019 | 0.0217 | 0.0217 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0019 | 0.0231 | 0.5034 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 0 % | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | ChEMBL. | 20485427 |
Inhibition (functional) | = 0 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 1.25 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 1.26 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 1.72 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 6 % | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 98 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition frequency index (IFI) (functional) | = 0.73 | Inhibition Frequency Index (IFI) | GSK. | 20485427 |
Percent growth inhibition (functional) | = -7 % | Percent inhibition of HepG2 growth (at 10 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 0 % | Percent inhibition of P. falciparum lactate dehydrogenase activity (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 6 % | Percent inhibition of P. falciparum Dd2 growth (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 98 % | Percent inhibition of P. falciparum 3D7 growth (at 2 uM) | GSK. | 20485427 |
XC50 (functional) | = 6.04 | XC50 determination of P. falciparum 3D7 growth | GSK. | 20485427 |
XC50 (functional) | = 0.91014 uM | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | ChEMBL. | 20485427 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.